The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
This marks Glenmark's first synthetic decapeptide injectable approval
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
